MRUS - Merus presents updated data for zenocutuzumab combo in HER2+ breast cancer patients

Merus (NASDAQ:MRUS) presents clinical data on zenocutuzumab (Zeno) in combination with trastuzumab and vinorelbine in patients with HER2+ metastatic breast cancer (MBC) at the San Antonio Breast Cancer Symposium in San Antonio, Texas. The primary endpoint of clinical benefit rate (CBR) at 24 weeks was met: 49% (18/37 patients; 90% CI 34 - 63). Confirmed responses (per investigator) were reported in 10 patients, including 2 patients with complete response (CR). Median duration of response was 4.2 months, including 2 patients with CR lasting 4.2 and 7.2+ months, and 8 patients with partial responses lasting from 2.6 to 12.4 months Median progression-free survival was 5.5 months; 7 patients (19%) were censored. Estimated overall survival rates at 12 and 24 months were 73% and 61%, respectively. The combination was observed to be well tolerated, with adverse events primarily related to chemotherapy.

For further details see:

Merus presents updated data for zenocutuzumab combo in HER2+ breast cancer patients